ANDA 202132, held by Xiromed. Ethinyl Estradiol; Norgestimate.
As of Nov 16, 2026, ANDA 202132 (Norgestimate And Ethinyl Estradiol), held by Xiromed, was first approved by FDA on Sep 9, 2015, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 9, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norgestimate And Ethinyl Estradiol0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Discontinued |
| Apr 29, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 21, 2018 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 21, 2018 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 9, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters